Idacio®

(adalimumab)

For GB healthcare professionals only. This content contains promotional and brand information.
 
Scroll down for IDACIO prescribing information and further product details. For adverse event reporting see bottom of webpage.

IDACIO 40 mg solution for injection in pre-filled pen.
IDACIO 40 mg solution for injection in pre-filled syringe.

The SmPC and Patient Leaflets are located on the electronic medicines compendium (emc). Note: by clicking the link you will leave the Fresenius Kabi GB website and be directed to the electronic medicines compendium website.

Filename
idacioprescribinginformation2024.pdf
Size
1 MB
Format
pdf
Idacio Prescribing Information

Details

The Idacio 40mg solution for injection in a pre-filled pen and pre-filled syringe are indicated for use in the following conditions. Please consult the SmPC before prescribing. Idacio treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of conditions for which Idacio is indicated.
  • Rheumatoid arthritis
  • Juvenile idiopathic arthritis
  • Axial spondyloarthritis
  • Psoriatic arthritis
  • Psoriasis
  • Paediatric plaque psoriasis
  • Hidradenitis suppurativa (HS)
  • Crohn's disease
  • Paediatric Crohn's disease
  • Ulcerative colitis
  • Paediatric ulcerative colitis
  • Uveitis
  • Paediatric Uveitis

Item codeDescriptionPresentationCase Qty
F0910202Idacio 40mgPre filled syringe 0.8ml2
F0910203Idacio 40mgPre filled pen 0.8ml2

Adverse events should be reported. Reporting forms and information can be found at:  https://yellowcard.mhra.gov.uk   Adverse events should also be reported to Fresenius Kabi Ltd. Cestrian Court, Eastgate Way, Manor Park, Runcorn, Cheshire, WA7 1NT Tel +44 (0)1928 533 575. Email:

 pharmacovigilance.gb@fresenius-kabi.com


 

 GB-IDA-2400016 October 2024